The following article features coverage from the American Society of Clinical Oncology 2019 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

Adherence to active surveillance (AS) protocols may be suboptimal outside of the trial setting, new findings suggest.

In an analysis of 346 men with low- to intermediate-risk prostate cancer (PCa) who chose AS, only 15% received recommended monitoring in the first 24 months, Ronald C. Chen, MD, MPH, of University of North Carolina, reported at the American Society of Clinical Oncology annual meeting.

In the first 6 months of AS, 67% patients received a PSA test and 70% had a digital rectal exam, in line with National Comprehensive Cancer Network (NCCN) guidelines. But only 35% received a guideline-directed biopsy within the first 18 months. Neither income, race, marital status, education, location, nor age, explained the gaps.

Related Articles

“This raises the question of whether we need to investigate whether active surveillance is a safe option when patients do not receive routine monitoring,” Dr Chen stated in a news release from the university. “Our goal is not to reduce the number of patients choosing active surveillance; rather, the results of this study should increase awareness and efforts to ensure that active surveillance patients are monitored rigorously.”

During the first 2 years, 16% of AS patients opted for treatment. Patient PCa anxiety (assessed by the MAX-PC) rather than cancer-related factors appeared to drive the decision. On multivariate analysis, MAX-PC scores and younger age significantly associated with conversion to treatment. At 2 years, 94% of men expressed no regret in choosing AS on the Clark’s PCa decision regret tool.

“While there are continued efforts to increase AS uptake, these results highlight the importance of behavioral interventions during active surveillance to reduce anxiety and improve monitoring adherence,” the authors stated.

Read more of Cancer Therapy Advisor‘s coverage of ASCO’s annual meeting by visiting the conference page.

References

Peterson S, Basak R, Himchan Moon D, et al. Population-based cohort of prostate cancer patients on active surveillance (AS): guideline adherence, conversion to treatment and decisional regret. J Clin Oncol 37, 2019 (suppl). Presented at the 2019 American Society of Clinical Oncology annual meeting in Chicago, May 31 to June 4. Abstract No: 6512.

Study: Men with Early-Stage Prostate Cancer Who Choose Active Surveillance Often Don’t Follow Monitoring Guidelines (news release). University of North Carolina; May 31, 2019.

This article originally appeared on Renal and Urology News